Grifols SA ADR (GRFS)

NASDAQ
Currency in USD
8.94
+0.07(+0.75%)
Real-time Data·
GRFS Scorecard
Full Analysis
High shareholder yield
GRFS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.788.96
52 wk Range
5.799.96
Key Statistics
Edit
Prev. Close
8.87
Open
8.92
Day's Range
8.78-8.96
52 wk Range
5.79-9.96
Volume
243.32K
Average Volume (3m)
864.49K
1-Year Change
24.93%
Book Value / Share
8.97
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRFS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.19
Upside
+36.30%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Grifols SA ADR News & Analysis

Show more

Grifols ADR Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify – CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Employees
23800

Compare GRFS to Peers and Sector

Metrics to compare
GRFS
Peers
Sector
Relationship
P/E Ratio
32.4x−1.0x−0.4x
PEG Ratio
-0.120.00
Price/Book
1.1x1.6x2.6x
Price / LTM Sales
0.9x4.3x3.0x
Upside (Analyst Target)
38.3%131.8%52.3%
Fair Value Upside
Unlock19.4%9.4%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 12.19
(+36.30% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
0.1334 / 0.1644
Revenue / Forecast
1.99B / 1.79B
EPS Revisions
Last 90 days

People Also Watch

19.219
NEON
+0.94%
5.320
A3M
-0.19%
3.260
DOMI
-0.91%
7.760
GRLSbn
-0.64%
17.45
AMX
+1.25%

FAQ

What Is the Grifols ADR (GRFS) Stock Price Today?

The Grifols ADR stock price today is 8.94

What Stock Exchange Does Grifols ADR Trade On?

Grifols ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Grifols ADR?

The stock symbol for Grifols ADR is "GRFS."

What Is the Grifols ADR Market Cap?

As of today, Grifols ADR market cap is 8.10B.

What Is Grifols ADR's Earnings Per Share (TTM)?

The Grifols ADR EPS (TTM) is 0.29.

When Is the Next Grifols ADR Earnings Date?

Grifols ADR will release its next earnings report on 23 Jul 2025.

From a Technical Analysis Perspective, Is GRFS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Grifols ADR Stock Split?

Grifols ADR has split 4 times.

How Many Employees Does Grifols ADR Have?

Grifols ADR has 23800 employees.

What is the current trading status of Grifols ADR (GRFS)?

As of 18 Jun 2025, Grifols ADR (GRFS) is trading at a price of 8.94, with a previous close of 8.87. The stock has fluctuated within a day range of 8.78 to 8.96, while its 52-week range spans from 5.79 to 9.96.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.